Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...

As for Uplizna, Amgen said that it is initiating regulatory filing activities to set it up for approval to treat MG. Last ...

Amgen (AMGN) shares slipped 3% in post-market trading after it reported Phase 3 data for two of its drugs, Uplizna and ...

Wells Fargo analyst Mohit Bansal maintained a Hold rating on Amgen (AMGN – Research Report) yesterday and set a price target of $335.00.

Bank of America Securities analyst Charlie CY Yang has maintained their neutral stance on AMGN stock, giving a Hold rating today. Charlie CY ...

Though Amgen reported encouraging results on two immunology drugs, Wall Street expresses skepticism as the data fell short ...

Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna ...

Amgen said on Tuesday that its drug helped improve daily activities including chewing and swallowing in patients suffering ...

Jefferies analyst Michael Yee in a note to investors called rocatinlimab’s atopic dermatitis data “modest,” noting that the ...

In an investor update on Tuesday, Amgen Inc (NASDAQ:AMGN) released data from Phase 3 trials of rocatinlimab and Uplizna ...

Medicines the company is developing for eczema and myasthenia gravis met their objectives in Phase 3 trials. But analysts ...